Commentary: Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma

被引:13
|
作者
Wu, Liusheng [1 ,2 ]
Li, Xiaoqiang [3 ]
Yan, Jun [1 ]
机构
[1] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Ctr Hepatobiliary Pancreat Dis, Sch Clin Med, Beijing 100084, Peoples R China
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 119077, Singapore
[3] Peking Univ, Shenzhen Hosp, Dept Thorac Surg, Shenzhen 518036, Guangdong, Peoples R China
来源
TRANSLATIONAL ONCOLOGY | 2024年 / 45卷
关键词
Machine learning; Intratumor heterogeneity signature; Survival prognosis; Cholangiocarcinoma; Immune microenvironment; Commentary;
D O I
10.1016/j.tranon.2024.101995
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Machine learning has made great progress in the field of medicine, especially in oncology research showing significant potential. In this paper, the application of machine learning in the study of cholangiocarcinoma was discussed. By developing a novel intra-tumor heterogeneity feature, the study successfully achieved accurate prediction of prognosis and immunotherapy effect in patients with cholangiocarcinoma. This study not only provides strong support for personalized treatment, but also provides key information for clinicians to develop more effective treatment strategies. This breakthrough marks the continuous evolution of machine learning in cancer research and brings new hope for the future development of the medical field. Our study lays a solid foundation for deepening the understanding of the biological characteristics of cholangiocarcinoma and improving the therapeutic effect, and provides a useful reference for more extensive cancer research.
引用
收藏
页数:3
相关论文
共 50 条
  • [1] Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma
    Chen, Xu
    Sun, Bo
    Chen, Yu
    Xiao, Yili
    Song, Yinghui
    Liu, Sulai
    Peng, Chuang
    TRANSLATIONAL ONCOLOGY, 2024, 43
  • [2] Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma
    Zhang, Wei
    Wang, Shuai
    MELANOMA RESEARCH, 2024, 34 (03) : 215 - 224
  • [3] Machine learning based intratumor heterogeneity signature for predicting prognosis and immunotherapy benefit in stomach adenocarcinoma
    Chen, Hongcai
    Zheng, Zhiwei
    Yang, Cui
    Tan, Tingting
    Jiang, Yi
    Xue, Wenwu
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [4] Machine Learning-based Macrophage Signature for Predicting Prognosis and Immunotherapy Benefits in Cholangiocarcinoma
    Huang, Junkai
    Chen, Yu
    Tan, Zhiguo
    Song, Yinghui
    Chen, Kang
    Liu, Sulai
    Peng, Chuang
    Chen, Xu
    CURRENT MEDICINAL CHEMISTRY, 2024,
  • [5] Machine learning developed an intratumor heterogeneity signature for predicting clinical outcome and immunotherapy benefit in bladder cancer
    Chen, Cheng
    Zhang, Jun
    Liu, Xiaoshuang
    Zhuang, Qianfeng
    Lu, Hao
    Hou, Jianquan
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2024, 13 (07)
  • [6] Machine learning developed a programmed cell death signature for predicting prognosis and immunotherapy benefits in lung adenocarcinoma
    Ding, Dongxiao
    Wang, Liangbin
    Zhang, Yunqiang
    Shi, Ke
    Shen, Yaxing
    TRANSLATIONAL ONCOLOGY, 2023, 38
  • [7] Machine learning based intratumor heterogeneity related signature for prognosis and drug sensitivity in breast cancer
    Chen, Hongcai
    Chen, Minna
    Yang, Cui
    Tang, Tingting
    Wang, Wende
    Xue, Wenwu
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [8] Machine learning developed a macrophage signature for predicting prognosis, immune infiltration and immunotherapy features in head and neck squamous cell carcinoma
    Wang, Yao
    Mou, Ya-Kui
    Liu, Wan-Chen
    Wang, Han-Rui
    Song, Xiao-Yu
    Yang, Ting
    Ren, Chao
    Song, Xi-Cheng
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [9] Machine learning developed immune-related exosome signature for prognosis and immunotherapy benefit in bladder cancer
    Xiaoting Luo
    Yi Luo
    Discover Oncology, 16 (1)
  • [10] An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma
    Liu, Cong
    Liu, Dingwei
    Wang, Fangfei
    Xie, Jun
    Liu, Yang
    Wang, Huan
    Rong, Jianfang
    Xie, Jinliang
    Wang, Jinyun
    Zeng, Rong
    Zhou, Feng
    Xie, Yong
    FRONTIERS IN MEDICINE, 2022, 9